Glofitamab Combination Improves Survival Compared to Rituximab in Relapsed/Refractory DLBCL

A recent clinical trial evaluated the efficacy and safety of combining glofitamab (Columvi), a bispecific antibody, with gemcitabine and oxaliplatin (GemOx) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). After a median follow-up period of 24.7 months, the group receiving glofitamab plus GemOx demonstrated a longer overall survival (OS) compared to the group receiving rituximab plus GemOx. Specifically, the median OS for the glofitamab group was not reached (not evaluable), while the median OS for the rituximab/GemOx group was 13.5 months. The safety profile of the glofitamab combination was consistent with the known risks associated with each of the individual drugs. DLBCL is an aggressive form of non-Hodgkin lymphoma, and treatment options for patients who relapse or do not respond to initial therapy are limited. The study's findings suggest that the glofitamab plus GemOx regimen may offer a new therapeutic option for this patient population. The results were reported by CancerNetwork.